News Report · Oncology

FDA Approves Pivekimab Sunirine for BPDCN: 69.7% CR Rate in CADENZA Trial

June 09, 2026

CR Rate

69.7%

Trial Name

CADENZA

Population

Adults with BPDCN

Dose

0.045 mg/kg IV every 3 weeks

Clinical Perspective

The approval of pivekimab sunirine for BPDCN provides a new treatment option for a rare and aggressive hematologic malignancy, with promising efficacy demonstrated in clinical trials. The significant CR rate of 69.7% in treatment-naïve patients highlights the potential for improved outcomes in this patient population. Ongoing research will be essential to understand the long-term safety and efficacy of this new therapy.

Dr. Rahul Verma · Oncology

Pivekimab sunirine (Decnupaz) achieved a complete remission (CR) rate of 69.7% in treatment-naïve patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) versus a control in the CADENZA trial (NCT03386513) [1].

Clinical Context

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an ultra-rare and aggressive hematologic malignancy characterized by the proliferation of plasmacytoid dendritic cells. The incidence of BPDCN is estimated to be less than 1 in 1 million individuals annually, making it a significant challenge for clinicians due to its rarity and aggressive nature. Current treatment options are limited, often relying on chemotherapy regimens that may not be effective for all patients. The approval of pivekimab sunirine represents a new therapeutic option targeting CD123, providing hope for improved outcomes in this challenging patient population.

Key Findings

The CADENZA trial showed pivekimab sunirine reduced the rate of complete remission (CR) by 69.7% versus treatment-naïve patients with BPDCN (CR 69.7%; 95% CI: 51.3, 84.4) [1].
The trial enrolled 84 adult patients with BPDCN, including 33 treatment-naïve and 51 relapsed or refractory cases [1].
Event rates: 69.7% CR in treatment-naïve patients versus 15.7% in relapsed or refractory patients [1].
The primary endpoint was the rate of complete remission or clinical complete remission (CR/CRc) [1].
In patients with relapsed or refractory BPDCN, 15.7% achieved CR/CRc [1].
Pivekimab sunirine is administered at a dose of 0.045 mg/kg intravenously over approximately 15-30 minutes once every three weeks until disease progression or unacceptable toxicity [1].
Clinicians should consult current prescribing information for full dosing guidance.

Safety & Tolerability

Hepatotoxicity reported with pivekimab sunirine — monitor liver function during treatment [1].
Infusion-related reactions reported — exact frequency not available in public source summary [1].
Edema reported — exact frequency not available in public source summary [1].
Sulfite allergic reactions reported [1].
Embryo-fetal toxicity — advise patients of reproductive potential to use effective contraception [1].
Complete adverse event profile available in the full prescribing information for pivekimab sunirine (Decnupaz) [1].

What This Means for Clinical Practice

Pivekimab sunirine is indicated for adults with BPDCN, including both treatment-naïve and relapsed patients. The data supports a CR rate of 69.7% in treatment-naïve patients, suggesting a significant improvement in outcomes for this rare malignancy. What further studies are needed to determine long-term efficacy and safety in diverse patient populations?

Study Design

The CADENZA trial was a multicenter, open-label, single-arm clinical trial that enrolled 84 adult patients with BPDCN, including both treatment-naïve and relapsed or refractory populations. The primary endpoint was the rate of complete remission or clinical complete remission (CR/CRc) with a median follow-up duration of 21.5 months for treatment-naïve patients and 24.1 months for relapsed or refractory patients. The trial was funded by AbbVie, and key limitations include its single-arm design and the small sample size, which may affect the generalizability of the results. Further data on long-term outcomes and safety profiles are still pending.

FAQ

What is pivekimab sunirine approved for?

Pivekimab sunirine (Decnupaz) is approved for the treatment of adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN) as of May 27, 2026, based on the CADENZA trial results.

How does pivekimab sunirine work?

Pivekimab sunirine is a CD123-directed antibody-drug conjugate that targets and delivers cytotoxic agents to BPDCN cells, promoting cell death and remission.

What is the recommended dose of pivekimab sunirine?

The recommended dose of pivekimab sunirine is 0.045 mg/kg intravenously over approximately 15-30 minutes once every three weeks until disease progression or unacceptable toxicity. Clinicians should consult current prescribing information for full dosing guidance.

What are the most common side effects of pivekimab sunirine?

Common side effects include hepatotoxicity, infusion-related reactions, edema, and allergic reactions to sulfites. Patients should be monitored for these adverse events during treatment.

FDA Approves Pivekimab Sunirine for BPDCN: 69.7% CR Rate in CADENZA Trial

FDA Approves Pivekimab Sunirine for BPDCN: 69.7% CR Rate in CADENZA Trial

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

What This Means for Clinical Practice

Study Design

FAQ

References

Get weekly drug updates for Oncology in your inbox.

Related Drug Updates

FDA Panel Votes Against Camizestrant for ESR1-Mutated Breast Cancer

FDA Approves Imlunestrant for ESR1-Mutated Breast Cancer: 5.5 Months PFS Improvement

FDA Advisory Panel Discusses Camizestrant for ESR1-Mutated Breast Cancer

Verified HCP Portal